Associated Press

In quiet debut, Alzheimer’s drug finds questions, skepticism

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed by questions about its price and how well it works. Several major medical centers remain undecided on whether to use Biogen’s Aduhelm, which is recommended for early stages of the disease. One neurology practice has even banned the company’s sales reps from its offices, citing concerns about the drug and its price, which can climb past $50,000 annually.

LEAVE A REPLY

Please enter your comment!
Please enter your name here